---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009179"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:14:11.508471+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lipocine Q1 net loss $1.9M; starts Phase 3 for PPD drug LPCN 1154

## Summary
- Net loss $1.9M ($0.35 diluted share) vs net income $3.5M ($0.66) in Q1 2024.
- Cash and equivalents $19.7M at March 31, 2025, down from $21.6M at Dec 31, 2024.
- Initiated outpatient Phase 3 study of LPCN 1154 (oral brexanolone) for postpartum depression; first patient dosing expected Q2 2025.
- Entered TLANDO license agreement for Brazil with Aché; exploring partnerships for LPCN 1154 and LPCN 2401.
- Plans proof-of-concept study for LPCN 2401 as adjunct to GLP-1 therapies, targeting elderly patients.

## SEC filing metadata
- accession: 0001641172-25-009179
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/0001641172-25-009179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225009179/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009179
- JSON: https://secwatch.observer/filing/0001641172-25-009179.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.